Quick Answer: Can You Get Weight Loss Injections on the NHS?
Yes, some weight management injections are available through the NHS in England, but the criteria depend on the medicine, your BMI, any weight related health conditions, and where you receive care.
Mounjaro (tirzepatide) is being introduced through both specialist weight management services and GP practices in phases. Wegovy (semaglutide) is also available through NHS weight management pathways, with eligibility depending on the specific NICE guidance and current NHS rollout. Saxenda (liraglutide) has also been recommended for certain adults through specialist weight management services.
Ozempic is different. Although it contains semaglutide and weight loss can occur during treatment, it is licensed for treating type 2 diabetes rather than specifically for weight management. It should not be presented as an NHS weight loss injection.
NHS access can therefore be more specific than simply asking whether your BMI qualifies. Your health conditions, clinical needs, local service arrangements and the medicine being considered can all affect whether treatment is available to you.
NHS Criteria for Mounjaro: Specialist Weight Management Service and the Current Rollout Explained
Mounjaro contains tirzepatide, a weekly injection used for weight management in eligible adults. NICE recommends tirzepatide alongside a reduced calorie diet and increased physical activity for adults with obesity who meet the relevant criteria.
The important point is that there are two parts to the current NHS picture: the wider NICE eligibility criteria and the phased approach being used for access through primary care.
Under the NICE criteria, tirzepatide can be considered for adults with a BMI of 35 or above and at least one weight related health condition, such as high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. A lower BMI threshold, usually reduced by 2.5 points, applies to people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African Caribbean ethnic backgrounds.
However, access through GP practices is being phased according to clinical need and NHS capacity. The current primary care rollout gives priority to people with four or more qualifying health conditions and a BMI of 40 or above in the first cohort. The BMI threshold is adjusted by 2.5 points for the ethnic groups covered by the guidance.
The next planned cohort covers people with a BMI of 35 to 39.9 who have four or more of the specified conditions. A later cohort is planned for people with a BMI of 40 or above who have three qualifying conditions. The rollout is being introduced over the first three years, so the criteria you see may depend on the current implementation stage.
The five qualifying conditions used for this phased primary care approach are:
- Type 2 diabetes
- High blood pressure
- Dyslipidaemia, meaning abnormal blood fat levels
- Cardiovascular disease
- Obstructive sleep apnoea
This means meeting the wider NICE criteria does not necessarily mean that a GP practice will offer Mounjaro immediately. Primary care access is being introduced in phases, while specialist weight management services can assess eligible patients under the wider NICE criteria.
If you think you may qualify, it is reasonable to speak with your GP or local weight management service. They can look at your BMI, health conditions and current NHS pathway rather than relying on BMI alone.
Mounjaro should also be used alongside lifestyle support. NHS guidance states that people prescribed tirzepatide should receive support around diet, physical activity and behaviour as part of their weight management care.
NHS Criteria for Wegovy
Wegovy (semaglutide) follows a different NHS pathway from Mounjaro. Under National Institute for Health and Care Excellence (NICE) guidance (TA875), Wegovy should be started and managed through a specialist Tier 3 weight management service, alongside lifestyle support such as a reduced calorie diet and increased physical activity.
For adults using Wegovy for weight management, the NHS criteria generally include a BMI of 35 or above, or a BMI of 30 or above with at least one weight related health condition. Lower BMI thresholds may apply to people from some ethnic backgrounds because health risks linked to excess weight can occur at a lower BMI.
There is also a separate cardiovascular disease pathway. Adults with established cardiovascular disease and a BMI of 27 kg/m² or above may be eligible for Wegovy to help reduce the risk of cardiovascular events, provided they meet the other clinical requirements. Your healthcare professional can confirm whether this route applies to you.
Your GP will usually refer you to a specialist Tier 3 weight management service if you may be eligible. Waiting times can vary depending on where you live and the availability of local services. Meeting the NICE criteria does not necessarily mean treatment will start immediately, as access depends on local NHS services and commissioning arrangements.
Wegovy should not be used alongside another GLP 1 receptor agonist unless specifically advised by a healthcare professional.
Is Ozempic Available on the NHS for Weight Loss and Type 2 Diabetes?
Not specifically for weight loss. Ozempic is licensed in the UK for the treatment of type 2 diabetes, where it can help with blood glucose control. Weight loss can occur while taking it, but this does not make Ozempic an NHS weight loss treatment.
If you have type 2 diabetes, a healthcare professional may prescribe Ozempic when it is clinically appropriate for managing your diabetes. If your main reason for seeking treatment is weight management and you do not have type 2 diabetes, Ozempic is not the NHS route for this purpose.
For NHS weight management, medicines such as Wegovy and Mounjaro have specific eligibility criteria and access routes. Your GP or weight management service can help you understand which option, if any, may be suitable for your circumstances.
NHS Access at a Glance
| Medicine | NHS route | General BMI threshold | Notes |
|---|---|---|---|
| Mounjaro (tirzepatide) | Phased GP practice rollout (QOF, from April 2026) | 40+ initially, widening to 35+ (with 4 of 5 conditions) | Not all practices participate yet, and access also requires participation in a nine-month wrap-around care programme |
| Wegovy (semaglutide) | Tier 3 specialist service via GP referral | 35+, or 30+ with a comorbidity | Used alongside a reduced-calorie diet and increased physical activity; NHS funding is typically limited to two years, and waiting times vary by area |
| Saxenda (liraglutide) | Tier 3 specialist service via GP referral | Broadly similar to Wegovy | Commissioning varies, sometimes more limited |
| Ozempic (semaglutide) | Type 2 diabetes treatment only | Not a weight-loss eligibility route | Weight loss is a secondary effect, not the indication |
Ethnicity-adjusted thresholds (typically 2.5 points lower) can apply across these NHS routes because of increased risk in people from Asian, Middle Eastern, Black African and African Caribbean ethnic backgrounds, even at the same body mass index BMI.
Why NHS Criteria Are Stricter Than Private Criteria
Private treatment through a GPhC registered pharmacy may be available to adults with a BMI of 30 or above, or 27 or above with a weight related health condition, following an individual clinical assessment. Private providers should also consider your medical history, current medicines and overall health, rather than relying on BMI alone.
This can make private eligibility broader than some current NHS routes, particularly during the phased rollout of Mounjaro. For example, the earlier NHS phases for Mounjaro focus on people with a BMI of 40 or above, or the relevant adjusted BMI threshold for some ethnic groups, together with multiple specified weight related health conditions.
The difference does not mean that NHS criteria are simply designed to make treatment harder to access. NHS access is being introduced in phases, with treatment prioritised for people considered to have the greatest clinical need. As the rollout develops, eligibility and access may change, so it is worth checking the current guidance rather than relying on older information.
Does It Matter Which Pharmacy or Provider I Use?
The underlying NHS eligibility criteria do not change depending on which pharmacy or provider you contact. Whether you use a high street pharmacy, supermarket pharmacy or online service, NHS treatment is based on the relevant NICE guidance and local NHS arrangements.
For private treatment, individual providers may have their own assessment process and prescribing policies. They should still carry out an appropriate clinical assessment before prescribing. If you see different BMI requirements advertised by different providers, check their current eligibility criteria and speak with the provider if you are unsure.
What If You Do Not Meet NHS Criteria?
Not meeting the current NHS criteria does not mean that there are no weight management options available to you. Depending on your circumstances, you may be able to access other NHS weight management services, structured weight management programmes or the NHS Diabetes Prevention Programme where appropriate.
Private treatment may also be an option for some adults who do not currently meet NHS criteria but do meet the eligibility requirements for private prescribing. A GPhC registered pharmacy should assess your health, medical history and current medicines before deciding whether treatment is appropriate.
If you think you may qualify for NHS treatment as the rollout expands, it is worth speaking with your GP. Your local service may have different arrangements depending on the current rollout phase and available resources.
If you are already receiving private treatment, speak with your private healthcare provider before making changes or assuming that you can move directly to NHS prescribing.
How to Find Out If You Qualify
The simplest way to understand whether you may qualify for NHS treatment is to speak with your GP or another suitable healthcare professional in primary care. They can look at your BMI, weight related health conditions and medical history, and explain whether an NHS prescription or another NHS weight management service may be appropriate.
For private treatment, an online consultation with a GPhC registered pharmacy such as EverydayMeds can assess whether treatment is suitable based on your individual circumstances, rather than BMI alone. If appropriate, this may include Mounjaro treatment or other weight management options.
